Discovery Park kicks off 2019 with focus on business development

Sandwich, Kent, UK - Discovery Park, a thriving high quality science park playing a key role in the South East of England’s life sciences community, has started 2019 with a strong focus on business development. As part of its ambitious plans for campus development, it is now seeking an anchor tenant for its world class 24,000 sq ft pilot scale manufacturing facility. Buying into the vision of the Park, the anchor tenant would play an important role in its development into a world leading centre of excellence in advanced manufacturing. For ambitious companies looking to expand, there is also laboratory and office space available in the iconic Building 500 where some of the most famous drugs in the world were discovered.

Formerly occupied by a global respiratory drugs manufacturer, Building 5181 is suitable for pilot scale small molecule drug development although it could be modified for biologicals manufacture. The sophisticated 220-acre Discovery Park site has excellent logistics as befits a major manufacturing site.

Building 500 is one of the most iconic locations on the Park as the former home of Pfizer R&D and manufacturing. There is flexible office plus chemistry and biology laboratory space from 2,000 sq ft available now in the world-class facility. Discovery Park provides extensive grow-on space for rapidly growing companies.

Discovery Park has grown to be a thriving part of the South East’s life science community in its six years as a high quality multi-business science campus. The growing tenant community includes Pfizer, which built the site’s reputation as a centre for drug discovery. Other tenants include Agalimmune, Algaecytes, Centauri Therapeutics, Genea Biomedx, Salvensis and Venomtech, and the Park and tenant community will be highlighted in events and conferences in 2019.

Mayer Schreiber, CEO of Discovery Park, said: “2018 was an important year for Discovery Park, with appointment of Martino Picardo as Chairman and further development of our strategy. In starting 2019 with a focus on an anchor tenant for the Building 518 manufacturing facility, as well as further occupiers for Building 500, the evolution of the Park continues. We look forward to welcoming new companies to our vibrant community here over the coming months.”

-ENDS-

1 For more information on Building 518 (the manufacturing facility) please click http://bit.ly/2EAGcjD and for Building 500 please click http://bit.ly/2R5gk5f.

To arrange a tour of either building please contact Lauren Moore on [email protected].

For further information and media opportunities, please contact Rebecca Daniels at Pillory Barn on 01622 684 407, or email: [email protected]


Editor’s Notes

ABOUT DISCOVERY PARK (WWW.DISCOVERY-PARK.CO.UK)

Discovery Park has grown to be a thriving part of the South East’s life science community in its six years as a multi-business science campus. The site offers high quality laboratory, office and manufacturing facilities, the space and support to expand, access to local finance, and a strong local scientific talent pool.

The growing tenant community includes Pfizer, which built the site’s reputation as a centre for drug discovery and discovered some of the most famous drugs in the world here. Other tenants include Agalimmune, Algaecytes, Centauri Therapeutics, Genea Biomedx and Salvensis. Discovery Park is home to 150+ companies employing 3,500 employees in total. With easy connections to London, Europe and the world Discovery Park is a great place to build and grow your biotech, medtech or pharma business.

Discover more via our website: – www.discovery-park.co.uk email: [email protected] or call: 01304 614060.

More within